NCT01428986

Safety Study of Maraviroc's Effect on Human Osteoclasts

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 16 (actual)
• Sponsor: National Center for Global Health and Medicine, Japan · Other Government
• Sex: All
• Age: 20 Years
• Healthy volunteers: Accepted

Summary

This study is to investigate the safety of maraviroc by examining whether there is bone metabolism dysfunction in actual use of maraviroc in human body, or not, measuring bone mineral density and markers for bone formation, desorption and chemokine.

Detailed description

An observational study to investigate the safety of maraviroc by examining whether there is bone metabolism dysfunction in actual use of maraviroc in human body, or not, measuring bone mineral density and markers for bone formation, desorption and chemokine.

Conditions

• HIV Infections
• AIDS

Interventions

Type	Name	Description
DRUG	Maraviroc	Maraviroc, 300mg BID for 72 weeks, except for cases with Efavirenz or Etravirine, 600mg BID for 72 weeks

Timeline

• Start date: 2009-11-01
• Primary completion: 2013-03-01
• Completion: 2014-03-01
• First posted: 2011-09-05
• Last updated: 2014-09-25

Locations

1 site across 1 country: Japan